FTC Settles Lawsuit With CVS Caremark Over Insulin Pricing Allegations

The Federal Trade Commission settled a lawsuit against CVS Caremark on July 14, 2026, over allegations that the company artificially inflated the price of insulin and impeded access to the diabetes treatment. Stat reported that CVS Caremark, one of the largest pharmacy benefit managers in the U.S. and owned by CVS Health, must make several changes to its dealings with employers, health plans, and pharmacies as part of the agreement.

The FTC maintained that the settlement will save Americans up to $8.5 billion in out-of-pocket costs over 10 years. Stat reported that the agency also estimated the deal will unlock up to $4.5 billion in further savings for patients through pharmacy counter rebates. In its complaint, the FTC alleged that CVS Caremark created a system of rebates that favored insulin sold at higher list prices.

Stat reported that the complaint also named Cigna’s Express Scripts and UnitedHealth’s Optum Rx as participants in the alleged rebate system.